Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Comparative Effectiveness Research

• Publication date

  2017-08-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/cer-2017-0037PMID 28840753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Indacaterol/Glycopyrronium Combination for COPD

  2017cited by this paper
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

  2017cited by this paper
• Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial

  2017cited by this paper
• Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary

  2017cited by this paper
• The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

  2017cited by this paper
• Long‐Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population‐Based Comparative Safety Study

  2017cited by this paper
• Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

  2017cited by this paper
• Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

  2017cited by this paper
• Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).

  2017cited by this paper
• LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

  2017cited by this paper
• Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

  2016cited by this paper
• Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis

  2016cited by this paper
• Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update

  2016cited by this paper
• Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

  2016cited by this paper
• S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study

  2016cited by this paper
• Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review

  2016cited by this paper
• A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.

  2016cited by this paper
• LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

  2016cited by this paper
• Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

  2016cited by this paper
• A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

  2015cited by this paper
• Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

  2015cited by this paper
• LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

  2015cited by this paper
• ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: questions and answers.

  2015cited by this paper
• Long-acting bronchodilators in COPD: where are we now and where are we going?

  2014cited by this paper
• Bronchodilators: current and future.

  2014cited by this paper
• Integrating patients into meaningful real-world research.

  2014cited by this paper
• Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

  2013cited by this paper
• Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis

  2013cited by this paper
• The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research

  2012cited by this paper
• Comparative effectiveness of drugs for chronic obstructive pulmonary disease.

  2012cited by this paper
• Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop.

  2011cited by this paper
• A call for action: Comparative effectiveness research in asthma.

  2011cited by this paper
• Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

  2011cited by this paper
• Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials.

  2010cited by this paper
• Acting on comparative effectiveness research in COPD.

  2010cited by this paper
• Comparative-effectiveness research--implications of the Federal Coordinating Council's report.

  2009cited by this paper
• [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin].

  2007cited by this paper
• Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)

  2007cited by this paper
• How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?

  2005cited by this paper
• Community-based intervention research: coping with the "noise" of real life in study design.

  2002cited by this paper

• Современные подходы к медикаментозному лечению пациентов с хронической обструктивной болезнью легких и туберкулезом (обзор литературы)

  2025cites this paper
• Features and significance of the early bronchodilatation effect of the first dose of a long-acting bronchodilator alone and in fixed combination in the treatment of chronic obstructive pulmonary disease

  2022cites this paper
• Comparative studies of dual bronchodilation in COPD.

  2021cites this paper
• Organic Cation Transporters (OCTs) in EpiAirway™, a Cellular Model of Normal Human Bronchial Epithelium

  2020cites this paper
• Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience

  2018cites this paper
• Effects of fixed combination of indacaterol/glycopyrronium in chronic obstructive pulmonary disease: state-of-the art review

  2018cites this paper
• An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?

  2018cites this paper